Germany-based Medigene AG ended the first half of 2022 with cash and cash equivalents of €39.4 million and a revenue-generating partnership with BioNTech SE to develop T cell receptor (TCR) based immunotherapies against cancer. Concurrently Selwyn Ho, an experienced business executive, took over the job of chief executive on 25 July, succeeding Dolores Schendel who will continue as chief scientific officer and head of research and development. Prof Schendel was previously both CEO and CSO.
